靶向VEGFR的放射性诊疗偶联药物研究进展
Research Progress of Radiotherapeutic Coupling Drugs Targeting VEGFR
DOI: 10.12677/acm.2026.163791, PDF,   
作者: 何 易：浙江工业大学药学院，浙江 杭州；肖 润*, 王雪强*：中国科学院杭州医学研究所，浙江 杭州
关键词: VEGFR；放射性诊疗一体化；肿瘤血管生成；靶向治疗；偶联药物设计；VEGFR； Integration of Radiation Diagnosis and Treatment； Tumor Angiogenesis； Targeted Therapy； Coupling Drug Design
摘要: VEGFR作为一种在肿瘤治疗方面有很大研究价值的重要靶点，主要负责血管生成的作用和调节。近年来，在精准医学(Theranostics)和辐射治疗结合领域，针对VEGFR的放射治疗药物相结合的药物已经成为一个热门的研究领域。本文对VEGFR的功能、通路作用以及其在疾病中所发生的重要性进行综述，对现有针对VEGFR的靶向治疗药物进行了总结和评价。在此基础上，重点分析了放射性诊疗偶联药物的构建原理、关键技术环节及VEGFR靶向药物的设计策略，包括抗体、多肽、小分子及适配体载体的应用与优化途径，旨在为靶向VEGFR的放射性诊疗一体化药物的创新研发提供理论支持与技术路径参考。
Abstract: As an important target with great research value in tumor therapy, VEGFR is mainly responsible for the role and regulation of angiogenesis. In recent years, in the field of combination of precision medicine and radiation therapy, the combination of radiotherapy drugs for VEGFR has become a hot research field. This article reviews the function, pathway role and the importance of VEGFR in disease, and summarizes and evaluates the existing targeted therapeutic drugs for VEGFR. On this basis, the construction principle, key technical links and the design strategy of VEGFR targeted drugs were analyzed, including the application and optimization of antibodies, peptides, small molecules and aptamer carriers, in order to provide theoretical support and technical path reference for the innovative research and development of VEGFR targeted integrated radiotherapeutic drugs.
文章引用：何易, 肖润, 王雪强. 靶向VEGFR的放射性诊疗偶联药物研究进展[J]. 临床医学进展, 2026, 16(3): 284-295. https://doi.org/10.12677/acm.2026.163791

参考文献

[1] 高诗特, 丁明雪, 邬月娇, 等. 靶向VEGFR抑制剂齐墩果酸类似物的合成及抗肿瘤活性研究[J]. 中国药物化学杂志, 2021, 31(11): 872-880.
[2] 蓝雪灵, 黄燕妮, 朱敏敏, 等. 抗VEGF及其受体分子靶向药物治疗肝癌机制的研究进展[J]. 中国临床药理学与治疗学, 2024, 29(6): 707-714.
[3] 王宁, 刘金彪. 乐伐替尼靶向调节VEGFR/PI3K/AKT治疗晚期甲状腺癌的作用机制[J]. 实用癌症杂志, 2021, 36(3): 415-418.
[4] 刘雯静, 秦长江. VEGF/VEGFR通路在胃癌靶向治疗中的研究进展[J]. 河南大学学报(医学版), 2021, 40(1): 68-72.
[5] 张娣, 董梅. 部分靶向药物在头颈部鳞状细胞癌靶向治疗中的应用进展[J]. 山东医药, 2021, 61(18): 106-111.
[6] 黄旭虎, 陈欢, 李可欣, 等. 肿瘤靶向放射性诊疗药物创新研发策略[J]. 原子能科学技术, 2025, 59(4): 769-782.
[7] 赵红博, 熊桂宏, 李明秋. 抑制肿瘤血管淋巴管生成的VEGFR分子机制及调控的研究进展[J]. 中国医学创新, 2023, 20(15): 184-188.
[8] 洪浩. 放射性核素偶联药物研发的优势与挑战[J]. 药学进展, 2023, 47(5): 321-323.
[9] 郑钧正. 放射诊疗的防护与安全是医疗设备应用安全和质量管理的重点[J]. 中国医疗设备, 2010, 25(9): 3-5.
[10] 刘丹, 李修齐, 刘书鹏, 等. 放射性核素偶联药物: 中国15年研发进程及最新政策支持[J]. 协和医学杂志, 2025, 16(4): 847-854.
[11] 王佳静, 张静烨, 董文彬, 等. 放射性核素偶联药物的研究进展及技术评价层面的思考[J]. 上海医药, 2024, 45(13): 10-13.
[12] 董国生, 陈欣, 李可欣, 等. 放射性核素偶联药物的研究进展及临床应用[J]. 药学进展, 2023, 47(5): 324-336.
[13] Libutti, S.K., Paciotti, G.F., Byrnes, A.A., Alexander, H.R., Gannon, W.E., Walker, M., et al. (2010) Phase I and Pharmacokinetic Studies of CYT-6091, a Novel Pegylated Colloidal Gold-RHTNF Nanomedicine. Clinical Cancer Research, 16, 6139-6149. [Google Scholar] [CrossRef] [PubMed]
[14] Wesselinova, D. (2011) Current Major Cancer Targets for Nanoparticle Systems. Current Cancer Drug Targets, 11, 164-183. [Google Scholar] [CrossRef] [PubMed]
[15] Masłowska, K., Halik, P.K., Tymecka, D., Misicka, A. and Gniazdowska, E. (2021) The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy. Cancers, 13, Article 1072. [Google Scholar] [CrossRef] [PubMed]
[16] Paudyal, B., Paudyal, P., Oriuchi, N., Hanaoka, H., Tominaga, H. and Endo, K. (2011) Positron Emission Tomography Imaging and Biodistribution of Vascular Endothelial Growth Factor with 64Cu‐Labeled Bevacizumab in Colorectal Cancer Xenografts. Cancer Science, 102, 117-121. [Google Scholar] [CrossRef] [PubMed]
[17] Fagin, J.A. and Wells, S.A. (2016) Biologic and Clinical Perspectives on Thyroid Cancer. New England Journal of Medicine, 375, 1054-1067. [Google Scholar] [CrossRef] [PubMed]
[18] Lee, I., Yoon, K.Y., Kang, C.M., Lin, X., Chen, X., Kim, J.Y., et al. (2012) Evaluation of the Angiogenesis Inhibitor KR-31831 in SKOV-3 Tumor-Bearing Mice Using 64Cu-DOTA-VEGF121 and MicroPET. Nuclear Medicine and Biology, 39, 840-846. [Google Scholar] [CrossRef] [PubMed]
[19] Lamartina, L., Durante, C., Filetti, S. and Cooper, D.S. (2015) Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A Systematic Review of the Literature. The Journal of Clinical Endocrinology & Metabolism, 100, 1748-1761. [Google Scholar] [CrossRef] [PubMed]
[20] Molinaro, E., Pieruzzi, L. and Viola, D. (2012) Radioiodine Post-Surgical Remnant Ablation in Patients with Differentiated Thyroid Cancer: News from the Last 10 Years. Journal of Endocrinological Investigation, 35, 16-20.
[21] Rosove, M.H., Peddi, P.F. and Glaspy, J.A. (2013) BRAF V600E Inhibition in Anaplastic Thyroid Cancer. New England Journal of Medicine, 368, 684-685. [Google Scholar] [CrossRef] [PubMed]
[22] Wagle, N., Grabiner, B.C., Van Allen, E.M., Amin-Mansour, A., Taylor-Weiner, A., Rosenberg, M., et al. (2014) Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 371, 1426-1433. [Google Scholar] [CrossRef] [PubMed]
[23] Wunderlich, A., Khoruzhyk, M., Roth, S., Ramaswamy, A., Greene, B.H., Doll, D., et al. (2013) Pretherapeutic Drug Evaluation by Tumor Xenografting in Anaplastic Thyroid Cancer. Journal of Surgical Research, 185, 676-683. [Google Scholar] [CrossRef] [PubMed]
[24] Kebebew, E. (2012) Anaplastic Thyroid Cancer: Rare, Fatal, and Neglected. Surgery, 152, 1088-1089. [Google Scholar] [CrossRef] [PubMed]
[25] Kniess, T. (2012) Radiolabeled Small Molecule Inhibitors of VEGFR-Recent Advances. Current Pharmaceutical Design, 18, 2867-2874. [Google Scholar] [CrossRef] [PubMed]
[26] Michalski, M.H. and Chen, X. (2010) Molecular Imaging in Cancer Treatment. European Journal of Nuclear Medicine and Molecular Imaging, 38, 358-377. [Google Scholar] [CrossRef] [PubMed]
[27] Bouziotis, P., Psimadas, D., Fani, M., Gourni, E., Loudos, G., Xanthopoulos, S., et al. (2006) Radiolabeled Biomolecules for Early Cancer Detection and Therapy via Angiogenesis Targeting. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 569, 492-496. [Google Scholar] [CrossRef] 
[28] Backer, M.V. and Backer, J.M. (2012) Imaging Key Biomarkers of Tumor Angiogenesis. Theranostics, 2, 502-515. [Google Scholar] [CrossRef] [PubMed]
[29] Nagengast, W.B., Lub-de Hooge, M.N., Oosting, S.F., den Dunnen, W.F.A., Warnders, F., Brouwers, A.H., et al. (2011) VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. Cancer Research, 71, 143-153. [Google Scholar] [CrossRef] [PubMed]
[30] Cai, W. and Hong, H. (2011) Peptoid and Positron Emission Tomography: An Appealing Combination American Journal of Nuclear Medicine and Molecular Imaging, 1, 76-79.
[31] Hao, G., Hajibeigi, A., León-Rodríguez, L.M., et al. (2011) Peptoid-Based PET Imaging of Vascular Endothelial Growth Factor Receptor (VEGFR) Expression. American Journal of Nuclear Medicine and Molecular Imaging, 1, 65-75.
[32] Lu, X. and Fu Wang, R. (2012) A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging. Current Pharmaceutical Design, 18, 1032-1040. [Google Scholar] [CrossRef] [PubMed]
[33] Rezazadeh, F., Sadeghzadeh, N., Abedi, S.M. and Abediankenari, S. (2018) 99mtc Labeled D(LPR): A Novel Retro-Inverso Peptide for VEGF Receptor-1 Targeted Tumor Imaging. Nuclear Medicine and Biology, 62, 54-62. [Google Scholar] [CrossRef] [PubMed]
[34] Giordano, R.J., Cardó-Vila, M., Salameh, A., Anobom, C.D., Zeitlin, B.D., Hawke, D.H., et al. (2010) From Combinatorial Peptide Selection to Drug Prototype (I): Targeting the Vascular Endothelial Growth Factor Receptor Pathway. Proceedings of the National Academy of Sciences, 107, 5112-5117. [Google Scholar] [CrossRef] [PubMed]
[35] Souris, J.S., Lee, C., Cheng, S., Chen, C., Yang, C., Ho, J.A., et al. (2010) Surface Charge-Mediated Rapid Hepatobiliary Excretion of Mesoporous Silica Nanoparticles. Biomaterials, 31, 5564-5574. [Google Scholar] [CrossRef] [PubMed]
[36] Kuchar, M., Oliveira, M.C., Gano, L., Santos, I. and Kniess, T. (2012) Radioiodinated Sunitinib as a Potential Radiotracer for Imaging Angiogenesis—Radiosynthesis and First Radiopharmacological Evaluation of 5-[125I]Iodo-Sunitinib. Bioorganic & Medicinal Chemistry Letters, 22, 2850-2855. [Google Scholar] [CrossRef] [PubMed]
[37] Sakr, T.M., El‐Safoury, D.M., Awad, G.A.S. and Motaleb, M.A. (2013) Biodistribution of 99mTc‐Sunitinib as a Potential Radiotracer for Tumor Hypoxia Imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 56, 392-395. [Google Scholar] [CrossRef] [PubMed]

为你推荐